Immune profiling | Biomarker platforms

Immune profiling and biomarker platforms to support pre-clinical research

WuXi Biology provides discovery and clinical biomarker services for immuno-oncology research. Our technology platform includes a CAP-certified pathology lab, a flow cytometry and molecular biology lab, and GCP compliance. Our team is composed of highly-trained immunologists, board-certified pathologists, and biomarker experts.

Flow Cytometry

Pathology/Multiplex IF

• FFPE preparation/IHC/IF to support pre-clinical pathology diagnosis for drug safety evaluation, efficacy evaluation, etc.
• Multiplex IF focusing on immune microenvironment analysis, including
  • Immune cell infiltration analysis
  • Spatial-proximity analysis
  • Secretory protein source determination
  • Complex tissue structure determination
  • Evaluation of gene expression regulation
• Provide biomarker testing services for clinical studies, including:
  • H&E and histology analysis
  • FFPE sample process and slide cutting
  • IHC/ICC,IF, EHC, TCT, FISH, DISH, RNAscope, and multiplex-IF

Case study: Optimization of human tumor dissociation process to eliminate hTIM-3 and hLAG-3 degradations

NanoString-based gene expression profiling

• Gene expression profiling with up to 800 genes in one panel
• Enabling GEP in difficult samples like FFPE
• Panel covering hot genes/pathways/function in immunology/oncology

Single-cell RNA sequencing platform and bioinformatics services

• One-stop service covering sample processing, library preparation, sequencing, and bioinformatics analysis.
• Enabling cell type identification and phenotyping, differential gene expression analysis, functional enrichment, and cell-cell interaction.

Molecular platform

• Quantitative polymerase chain reaction (qPCR) to support efficacy and safety evaluation (e.g. target gene copy number variation in CAR-T cells, and replication competent lentivirus (RCL) level in CAR-T cells).
• cMET exon14 skipping and EGFR mutation testing.